Deregulated miRNAs in osteoporosis: effects in bone metastasis.
Animals
Bone Neoplasms
/ complications
Breast Neoplasms
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Circulating MicroRNA
/ metabolism
Esophageal Neoplasms
/ genetics
Esophageal Squamous Cell Carcinoma
/ genetics
Female
Humans
Lung Neoplasms
/ genetics
Male
MicroRNAs
/ metabolism
Multiple Myeloma
/ genetics
Osteoporosis
/ complications
Prostatic Neoplasms
/ genetics
Bone metastasis
Osteolysis
Osteoporosis
miRNA
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
25
02
2019
accepted:
28
05
2019
revised:
22
05
2019
pubmed:
31
5
2019
medline:
18
10
2019
entrez:
1
6
2019
Statut:
ppublish
Résumé
Starting from their role exerted on osteoblast and osteoclast differentiation and activity pathways, microRNAs (miRNAs) have been recently identified as regulators of different processes in bone homeostasis. For this purpose, in a recent review, we highlighted, as deregulated miRNAs could be involved in different bone diseases such as osteoporosis. In addition, recent studies supported the concept that osteoporosis-induced bone alterations might offer a receptive site for cancer cells to form bone metastases, However, to date, no data on specific-shared miRNAs between osteoporosis and bone metastases have been considered and described to clarify the evidence of this link. The main goal of this review is to underline as deregulated miRNAs in osteoporosis may have specific roles in the development of bone metastases. The review showed that several circulating osteoporotic miRNAs could facilitate tumor progression and bone-metastasis formation in several tumor types, i.e., breast cancer, prostate cancer, non-small-cell lung cancer, esophageal squamous cell carcinoma, and multiple myeloma. In detail, serum up-regulation of pro-osteoporotic miRNAs, as well as serum down-regulation of anti-osteoporotic miRNAs are common features of all these tumors and are able to promote bone metastasis. These results are of key importance and could help researcher and clinicians to establish new therapeutic strategies connected with deregulation of circulating miRNAs and able to interfere with pathogenic processes of osteoporosis, tumor progressions, and bone-metastasis formation.
Identifiants
pubmed: 31147752
doi: 10.1007/s00018-019-03162-w
pii: 10.1007/s00018-019-03162-w
doi:
Substances chimiques
Circulating MicroRNA
0
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3723-3744Références
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s
pubmed: 17062708
Immunology. 2007 Apr;120(4):573-9
pubmed: 17343616
Cell. 2007 Jun 29;129(7):1401-14
pubmed: 17604727
Nature. 2007 Oct 11;449(7163):682-8
pubmed: 17898713
Mol Immunol. 2009 Jul;46(11-12):2161-6
pubmed: 19477525
J Clin Invest. 2009 Dec;119(12):3666-77
pubmed: 19920351
J Cell Biochem. 2010 Apr 1;109(5):866-75
pubmed: 20039311
Scand J Clin Lab Invest. 2010 Sep;70(5):338-42
pubmed: 20509757
Eur Respir J. 2011 Mar;37(3):617-23
pubmed: 20595154
Gynecol Oncol. 2010 Dec;119(3):586-93
pubmed: 20801493
Prostate. 2011 Feb 15;71(3):326-31
pubmed: 20842666
Clin Chem. 2010 Dec;56(12):1871-9
pubmed: 20943850
Clin Chem. 2011 Jan;57(1):84-91
pubmed: 21036945
J Cell Biochem. 2011 Mar;112(3):750-5
pubmed: 21328448
Int J Cancer. 2012 Apr 1;130(7):1620-8
pubmed: 21557218
Chin J Cancer. 2011 Jun;30(6):407-14
pubmed: 21627863
BMC Cancer. 2011 Aug 24;11:374
pubmed: 21864403
BMC Cancer. 2011 Sep 15;11:393
pubmed: 21920043
Biochem Biophys Res Commun. 2011 Oct 14;414(1):233-9
pubmed: 21951844
Anticancer Res. 2011 Dec;31(12):4423-8
pubmed: 22199310
Breast Cancer Res Treat. 2012 Aug;134(3):933-41
pubmed: 22350790
Breast Cancer Res. 2012 Feb 21;14(1):R34
pubmed: 22353773
PLoS One. 2012;7(4):e34641
pubmed: 22506038
PLoS One. 2012;7(4):e34210
pubmed: 22523546
J Cancer Res Clin Oncol. 2012 Dec;138(12):2045-50
pubmed: 22806310
J Int Med Res. 2012;40(3):859-66
pubmed: 22906258
PLoS One. 2012;7(8):e43268
pubmed: 22937028
Acta Pharmacol Sin. 2013 Feb;34(2):309-13
pubmed: 22983388
J Cancer Res Clin Oncol. 2013 Feb;139(2):223-9
pubmed: 23052693
J Bone Miner Res. 2013 Mar;28(3):559-73
pubmed: 23074166
Nat Med. 2013 Jan;19(1):93-100
pubmed: 23223004
PLoS One. 2013;8(1):e53141
pubmed: 23301032
Dis Markers. 2013;34(3):163-9
pubmed: 23334650
Int J Mol Sci. 2013 Apr 10;14(4):7757-70
pubmed: 23574937
Clin Cancer Res. 2013 Aug 15;19(16):4477-87
pubmed: 23797906
J Bone Miner Res. 2014 Feb;29(2):338-47
pubmed: 23821519
Cancer Cell. 2013 Oct 14;24(4):542-56
pubmed: 24135284
Mol Biol Rep. 2014 Mar;41(3):1257-66
pubmed: 24390317
Bonekey Rep. 2013 Oct 02;2:437
pubmed: 24422135
J Bone Miner Res. 2014 Aug;29(8):1718-28
pubmed: 24431276
Oncotarget. 2014 Feb 15;5(3):824-40
pubmed: 24583788
Mol Med Rep. 2014 May;9(5):1820-6
pubmed: 24604278
PLoS One. 2014 Mar 20;9(3):e92292
pubmed: 24651474
Clin Cancer Res. 2014 Jun 1;20(11):2922-32
pubmed: 24687923
Biomed Res Int. 2014;2014:284836
pubmed: 24696846
Int J Oncol. 2014 Jul;45(1):401-10
pubmed: 24820027
PLoS One. 2014 May 12;9(5):e97098
pubmed: 24820117
Lancet Oncol. 2014 Aug;15(9):997-1006
pubmed: 25035292
Nature. 2014 Aug 28;512(7515):431-5
pubmed: 25043055
Biomarkers. 2014 Nov;19(7):553-6
pubmed: 25231354
Calcif Tissue Int. 2015 Jan;96(1):30-7
pubmed: 25432767
Oncotarget. 2015 Jan 1;6(1):441-57
pubmed: 25436980
Oncogene. 2015 Sep 3;34(36):4767-76
pubmed: 25531317
Neoplasma. 2015;62(2):250-8
pubmed: 25591590
Int J Mol Sci. 2015 Jan 30;16(2):3148-62
pubmed: 25647415
Ann Lab Med. 2015 Mar;35(2):226-32
pubmed: 25729725
Oncotarget. 2015 May 30;6(15):13772-89
pubmed: 25944696
Med Sci Monit. 2015 May 27;21:1527-34
pubmed: 26013661
Bone. 2015 Oct;79:43-51
pubmed: 26026730
Oncotarget. 2015 May 30;6(15):13387-401
pubmed: 26033453
Clin Chem. 2015 Aug;61(8):1098-106
pubmed: 26056355
Bone. 2015 Oct;79:176-82
pubmed: 26057367
Oncogene. 2016 Mar 3;35(9):1180-92
pubmed: 26073083
Biomed Res Int. 2015;2015:421746
pubmed: 26247020
Histol Histopathol. 2016 Jan;31(1):83-93
pubmed: 26254457
Biomed Pharmacother. 2015 Oct;75:185-90
pubmed: 26337230
J Mol Diagn. 2015 Nov;17(6):669-78
pubmed: 26433312
Bonekey Rep. 2015 Oct 28;4:753
pubmed: 26539296
BMC Med Genomics. 2015 Nov 10;8:75
pubmed: 26555194
EBioMedicine. 2015 Aug 04;2(10):1377-85
pubmed: 26629532
Oncol Rep. 2016 Mar;35(3):1449-56
pubmed: 26708917
Genet Mol Res. 2015 Dec 22;14(4):17684-91
pubmed: 26782413
Carcinogenesis. 2016 May;37(5):461-70
pubmed: 26785733
Oncotarget. 2016 Apr 12;7(15):19589-600
pubmed: 26995755
Oncotarget. 2016 Jul 12;7(28):44803-44820
pubmed: 27027241
Tumour Biol. 2016 Sep;37(9):12023-12032
pubmed: 27164937
Cell Physiol Biochem. 2016;39(1):253-65
pubmed: 27337099
J Clin Endocrinol Metab. 2016 Nov;101(11):4125-4134
pubmed: 27552543
Bone Res. 2016 Apr 26;4:16009
pubmed: 27563484
Neoplasma. 2016;63(6):941-951
pubmed: 27596294
J Leukoc Biol. 2017 Jun;101(6):1289-1300
pubmed: 27677834
Curr Osteoporos Rep. 2016 Oct 13;:null
pubmed: 27734322
Cancer Lett. 2017 Jan 1;384:1-8
pubmed: 27746161
Oncotarget. 2016 Nov 22;7(47):76966-76983
pubmed: 27765913
Sci Rep. 2016 Nov 08;6:36347
pubmed: 27821865
Eur J Endocrinol. 2017 Feb;176(2):169-176
pubmed: 27836951
Clin Transl Oncol. 2017 May;19(5):633-640
pubmed: 27896643
Wien Klin Wochenschr. 2016 Dec;128(Suppl 7):519-526
pubmed: 27900532
J Cell Physiol. 2017 Jul;232(7):1826-1834
pubmed: 27925188
Sci Rep. 2017 Jan 10;7:40487
pubmed: 28071724
Sci Rep. 2017 Feb 27;7:43191
pubmed: 28240263
Biomed Pharmacother. 2017 May;89:1178-1186
pubmed: 28320084
Carcinogenesis. 2017 May 1;38(5):492-503
pubmed: 28334277
Hum Pathol. 2017 Jun;64:44-52
pubmed: 28412211
Yonsei Med J. 2017 Jul;58(4):697-702
pubmed: 28540980
Int J Mol Sci. 2017 Oct 10;18(10):null
pubmed: 28994735
Sci Rep. 2017 Nov 20;7(1):15861
pubmed: 29158518
Oncotarget. 2017 Sep 27;8(54):92454-92469
pubmed: 29190930
J Thorac Dis. 2017 Oct;9(10):3735-3746
pubmed: 29268381
Exp Ther Med. 2017 Dec;14(6):5464-5472
pubmed: 29285077
Clin Exp Pharmacol Physiol. 2018 Jun;45(6):602-613
pubmed: 29288578
Biochem Cell Biol. 2018 Oct;96(5):627-635
pubmed: 29334613
Oncotarget. 2017 Nov 28;8(69):113598-113613
pubmed: 29371932
Tissue Eng Part A. 2019 Jan;25(1-2):24-33
pubmed: 29490603
J Clin Endocrinol Metab. 2018 May 1;103(5):1985-1996
pubmed: 29506076
Sci Rep. 2018 Mar 20;8(1):4867
pubmed: 29559644
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
Biochem Biophys Res Commun. 2018 Jun 22;501(2):486-493
pubmed: 29746865
Front Endocrinol (Lausanne). 2018 Apr 27;9:202
pubmed: 29780354
Oncol Lett. 2018 Jun;15(6):9081-9086
pubmed: 29805640
Biochim Biophys Acta Gen Subj. 2018 Sep;1862(9):1893-1901
pubmed: 29885361
Oncol Lett. 2018 Jul;16(1):1196-1204
pubmed: 29963194
Breast. 2018 Oct;41:42-50
pubmed: 30007267
Cancer Res. 2018 Sep 15;78(18):5259-5273
pubmed: 30042152
Oncol Lett. 2018 Sep;16(3):3140-3144
pubmed: 30127906
Gene. 2018 Dec 30;679:19-27
pubmed: 30171938
Curr Osteoporos Rep. 2018 Dec;16(6):642-647
pubmed: 30203251
J Bone Miner Res. 2019 Jan;34(1):135-144
pubmed: 30321475
Int Urol Nephrol. 2018 Dec;50(12):2193-2200
pubmed: 30324582
Bone. 2019 Mar;120:371-386
pubmed: 30503955
J Exp Clin Cancer Res. 2018 Dec 4;37(1):301
pubmed: 30514328
Oncol Lett. 2019 Jan;17(1):398-405
pubmed: 30655780
Bone. 2019 May;122:52-75
pubmed: 30772601